Company intelligence / Profile preview

Respinova

Ownership: Private
Development stage: Commercial

Overview

The Pulsehaler device has received FDA 510(k) clearance for use in patients with respiratory problems. Clinical trials have demonstrated improvements in exercise capacity, lung function, and quality of life for COPD patients. The technology uses proprietary pulses of pressure to open collapsed airways and facilitate inhaled drug delivery or mucus clearance. It represents a novel approach to treating the core pathophysiology of COPD and related conditions.

Therapeutic areas: Pulmonology
Modalities: Device (specifically non-invasive respiratory device)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Pulsehaler

Commercial

Indications: COPD, Asthma, Cystic fibrosis

Partnerships

Chiesi Spain/Richi Entrepreneurs grant recipient

Beyond the preview

Go deeper on Respinova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respinova.

Explore the full profile